)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Belite Bio
Belite Bio (BLTE) investor relations material
Belite Bio Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Nov, 2026
Executive summary
FDA accepted the tinlarebant STGD1 NDA for Priority Review, set a Feb. 12, 2027 PDUFA date, and will not convene an advisory committee.
Regulatory filings advanced in Japan, Singapore, the U.K. and Switzerland; launch preparations include payer engagement and commercial teams.
Q3 GAAP net loss was $30.3M; quarter-end cash, cash equivalents and U.S. Treasury bills totaled $774M.
Financial highlights
Q3 R&D was $15.5M ($14.7M excluding share-based compensation) vs. $10.3M ($8.0M); SG&A was $21.4M ($16.3M) vs. $12.7M ($2.1M). GAAP operating expenses were $36.9M; 9M expenses were $104.5M.
Q3 GAAP net loss was $30.3M, or $0.75/share, vs. $21.7M, or $0.65/share; 9M net loss was $85.6M, or $2.13/share.
Excluding share-based compensation, Q3 net loss was $24.3M, or $0.60/share, vs. $8.8M; 9M adjusted net loss was $59.7M, or $1.49/share.
Q3 other income was $6.7M and 9M other income was $18.9M, primarily from interest on deposits and U.S. Treasury securities.
At Sept. 30, 2026, cash and equivalents were $271.3M and U.S. Treasury bills and notes were $502.7M, totaling $774M vs. $780M at Q2 2026.
Outlook and guidance
FDA review of the STGD1 NDA is ongoing, with a Feb. 12, 2027 PDUFA date; current cash runway is expected to support potential commercialization and continued pipeline advancement.
Commercial preparations include early payer and pharmacy benefit manager engagement, with launch readiness contingent on approval; a Japan commercial team is in place and direct marketing is planned if approved.
PHOENIX, tinlarebant’s geographic atrophy trial, is expected to undergo an interim analysis; the GA interim-analysis design is unconfirmed and planned after the Feb. 2027 PDUFA.
A pediatric PIP study at Moorfields Eye Hospital is expected to start before year-end 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Belite Bio
- Tinlarebant slowed Stargardt lesion progression 36%; FDA priority review is underway.BLTE
Morgan Stanley 24th Annual Global Healthcare Conference - Tinlarebant shows strong efficacy and safety for Stargardt disease, with broad launch readiness.BLTEH.C. Wainwright 28th Annual Global Investment Conference
- Tinlarebant nears approval for Stargardt disease, showing strong efficacy and broad commercial readiness.BLTE12th Annual Cantor Fitzgerald Global Healthcare Conference
- Tinlarebant nears FDA decision for Stargardt disease, with broad access and strong payer support expected.BLTEWells Fargo 21st Annual Healthcare Conference
- Tinlarebant slowed Stargardt lesion growth and is under FDA priority review for a 2027 launch.BLTEInvestor update
- Emerging therapies for IRDs show strong efficacy, safety, and potential to transform patient outcomes.BLTEH.C. Wainwright 6th Annual Ophthalmology Virtual Conference
- Tinlarebant achieved a 36% reduction in lesion growth for Stargardt disease with strong safety data.BLTECompany presentation
- FDA Priority Review for tinlarebant in STGD1 advances, supported by strong data and cash reserves.BLTEQ2 2026
- Tinlarebant's Phase III trials progress with strong safety data and $157.4M cash reserves.BLTEQ1 2025
Next Belite Bio earnings date
Q4 20263 Mar, 2027
Belite Bio
Next Belite Bio earnings date
Q4 20263 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Belite Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing novel therapeutics targeting retinal degenerative eye diseases and certain metabolic diseases. The company's primary focus includes conditions such as atrophic age-related macular degeneration (AMD) and autosomal recessive Stargardt disease type 1 (STGD1), which can lead to permanent blindness. Additionally, Belite Bio is exploring treatments for metabolic disorders like non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Belite Bio, Inc. was founded in 2016 and is headquartered in San Diego, California. The company's shares are listed on the NASDAQ.